NewAmsterdam Pharma Company NV
NAMS21.450USD
+0.170+0.80%
Market hours （ET）Quotes delayed by 15 min
2.41BMarket Cap
LossP/E TTM
More Details of NewAmsterdam Pharma Company NV Company
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
Company Info
Ticker SymbolNAMS
Company nameNewAmsterdam Pharma Company NV
IPO dateNov 23, 2022
CEODr. Michael Harvey Davidson, M.D.
Number of employees68
Security typeOrdinary Share
Fiscal year-endNov 23
AddressGooimeer 2-35
CityNAARDEN
Stock exchangeNASDAQ Global Market Consolidated
CountryNetherlands
Postal code1411 DC
Phone31352062971
Websitehttps://ir.newamsterdampharma.com/
Ticker SymbolNAMS
IPO dateNov 23, 2022
CEODr. Michael Harvey Davidson, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
6.96K
--
Mr. Wouter Joustra
Mr. Wouter Joustra
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Ms. Louise Kooij
Ms. Louise Kooij
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Ms. Adele M. Gulfo
Ms. Adele M. Gulfo
Independent Director
Independent Director
--
--
Dr. Louis Lange, M.D., Ph.D.
Dr. Louis Lange, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Marc Ditmarsch, M.D.
Dr. Marc Ditmarsch, M.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Douglas Kling
Mr. Douglas Kling
Chief Operating Officer
Chief Operating Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
6.96K
--
Mr. Wouter Joustra
Mr. Wouter Joustra
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Ms. Louise Kooij
Ms. Louise Kooij
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Ms. Adele M. Gulfo
Ms. Adele M. Gulfo
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Thu, Jul 24
Updated: Thu, Jul 24
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Frazier Life Sciences Management, L.P.
14.36%
Bain Capital Life Sciences Investors, LLC
9.55%
Forbion Capital Partners
9.49%
Capital Research Global Investors
9.26%
RA Capital Management, LP
9.03%
Other
48.31%
Shareholders
Shareholders
Proportion
Frazier Life Sciences Management, L.P.
14.36%
Bain Capital Life Sciences Investors, LLC
9.55%
Forbion Capital Partners
9.49%
Capital Research Global Investors
9.26%
RA Capital Management, LP
9.03%
Other
48.31%
Shareholder Types
Shareholders
Proportion
Investment Advisor
35.92%
Investment Advisor/Hedge Fund
23.68%
Venture Capital
21.76%
Private Equity
14.36%
Hedge Fund
13.18%
Research Firm
1.42%
Family Office
0.71%
Individual Investor
0.45%
Bank and Trust
0.28%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
262
128.82M
114.74%
+5.59M
2025Q1
255
126.71M
112.87%
+7.17M
2024Q4
216
108.34M
98.72%
+13.96M
2024Q3
194
82.73M
88.90%
-12.05M
2024Q2
184
81.92M
90.19%
-12.22M
2024Q1
155
81.92M
90.50%
-4.21M
2023Q4
117
72.34M
86.57%
-9.73M
2023Q3
116
71.44M
85.50%
-13.42M
2023Q2
109
71.10M
86.48%
+7.09M
2023Q1
105
62.44M
76.40%
-1.21M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Frazier Life Sciences Management, L.P.
16.12M
14.36%
+200.00K
+1.26%
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
10.72M
9.55%
--
--
Mar 31, 2025
Forbion Capital Partners
10.66M
9.49%
-279.14K
-2.55%
Apr 15, 2025
Capital Research Global Investors
8.83M
7.86%
--
--
May 31, 2025
RA Capital Management, LP
10.14M
9.03%
+1.29M
+14.63%
Mar 31, 2025
Viking Global Investors LP
6.98M
6.22%
--
--
Mar 31, 2025
Capital World Investors
6.80M
6.06%
+5.78M
+569.10%
Mar 31, 2025
Deerfield Management Company, L.P.
4.10M
3.66%
-210.38K
-4.88%
Mar 31, 2025
Wellington Management Company, LLP
3.54M
3.15%
+1.23M
+52.99%
Mar 31, 2025
Jennison Associates LLC
3.97M
3.54%
-28.35K
-0.71%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ALPS Medical Breakthroughs ETF
1.38%
Global X Guru Index ETF
1.17%
Virtus LifeSci Biotech Clinical Trials ETF
0.78%
Invesco Dorsey Wright SmallCap Momentum ETF
0.35%
First Trust Small Cap Growth AlphaDEX Fund
0.29%
ProShares Ultra Nasdaq Biotechnology
0.23%
Invesco Nasdaq Biotechnology ETF
0.23%
iShares Biotechnology ETF
0.12%
First Trust Small Cap Core Alphadex Fund
0.11%
First Trust IPOX Europe Equity Opportunities ETF
0.09%
View more
ALPS Medical Breakthroughs ETF
Proportion1.38%
Global X Guru Index ETF
Proportion1.17%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.78%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.35%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.29%
ProShares Ultra Nasdaq Biotechnology
Proportion0.23%
Invesco Nasdaq Biotechnology ETF
Proportion0.23%
iShares Biotechnology ETF
Proportion0.12%
First Trust Small Cap Core Alphadex Fund
Proportion0.11%
First Trust IPOX Europe Equity Opportunities ETF
Proportion0.09%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
